Sopharma Trading ADXBUL:SFT +0.68%84 EBITDA Margin % is 5.47% as of Mar. 2026, which is 69% above its 10-year median of 3.24. GuruFocus rates XBUL:SFT with a GF Score™ of 84/100 and a GF Value™ of €7.60 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 117 Medical Distribution companies, Sopharma Trading AD ranks better than 55.56% on this metric.
Sopharma Trading AD (XBUL:SFT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sopharma Trading AD EBITDA Margin % Related Terms
Sopharma Trading AD EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:SFT vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Sopharma Trading AD's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma Trading AD (XBUL:SFT) has a EBITDA Margin % of 5.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sopharma Trading AD and its competitors. This is 69% above median its historical median of 3.24. Over the past decade, Sopharma Trading AD's EBITDA Margin % has ranged from 2.51 to 5.56. According to the industry distribution chart, Sopharma Trading AD ranks #52 out of 117 companies in the Medical Distribution industry, placing it in the top 44.4%.
Is Sopharma Trading AD's EBITDA Margin % too high?
Sopharma Trading AD's current EBITDA Margin % of 5.47% is 69% above median its 10-year median of 3.24. Over the past 10 years, this metric has ranged from a low of 2.51 to a high of 5.56. The Medical Distribution industry median EBITDA Margin % is 4.28. Sopharma Trading AD's value of 5.47% is 27.8% above this industry median. Based on the distribution chart, Sopharma Trading AD ranks #52 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sopharma Trading AD has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #52 out of 117 companies for EBITDA Margin %. This puts Sopharma Trading AD in the upper half of its industry. The industry median EBITDA Margin % is 4.28. Sopharma Trading AD's value of 5.47% is 27.8% above this benchmark. Historically, Sopharma Trading AD's own EBITDA Margin % has ranged from 2.51 to 5.56 over the past decade. While the company's 10-year median is 3.24 vs. the industry median of 4.28, Sopharma Trading AD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current EBITDA Margin % of 5.47% is 27.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current EBITDA Margin % is 5.47%, which is 69% above median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.60, compared to a current price of €2.94 — trading 61.3% below its estimated fair value. The current EBITDA Margin % is 5.47%, which is 69% above median its 10-year median of 3.24 and 27.8% above the Medical Distribution industry median of 4.28. Sopharma Trading AD's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current EBITDA Margin % is 5.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.94 is trading 61.3% below its estimated GF Value™ of €7.60.
GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.
Key valuation signals for XBUL:SFT:
EBITDA Margin %: 5.47% (69% above median its 10-year median of 3.24)
GF Value™: €7.60 vs. price of €2.94 (61.3% below fair value)
Industry Position: 27.8% above the Medical Distribution median (#52 of 117)
No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
84GF Score
Get the complete analysis for XBUL:SFT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:SFT has been successfully added to your 
